Chemotherapy for Breast Cancer

Not currently recruiting at 550 trial locations

Age: 18+

Sex: Any

Trial Phase: Phase 3

Sponsor: SWOG Cancer Research Network

Must not be taking: Anthracyclines, Taxanes

Disqualifiers: Congestive heart failure, Angina, HIV, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 6

Duration: 24-30 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores which combination of chemotherapy drugs best treats breast cancer after surgery. It tests various drug combinations, including doxorubicin (Adriamycin), cyclophosphamide (Cytoxan), and paclitaxel (Taxol), to determine which most effectively stops cancer growth or eliminates remaining cancer cells. Individuals who have undergone surgery for stage I to III breast cancer and meet specific criteria, such as having a high-risk tumor or certain hormone receptor statuses, might be suitable candidates. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatments.

Do I have to stop taking my current medications for this trial?

The trial protocol does not specify whether you need to stop taking your current medications. However, it does mention that no prior chemotherapy for this breast cancer is allowed, so you may need to discuss your current treatments with the trial team.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

A previous study found that patients receiving a combination of doxorubicin, cyclophosphamide, and paclitaxel generally tolerated the treatment well. These drugs often treat early-stage breast cancer. Research shows that common side effects include nausea, tiredness, and hair loss, typical for chemotherapy. Serious side effects can occur but are less common. Doxorubicin has been associated with heart-related issues, but doctors closely monitor this during treatment. Overall, many patients have used this combination safely, with doctors vigilant for any potential side effects. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about these treatments for breast cancer because they combine powerful chemotherapy drugs with supportive medications to enhance effectiveness and manage side effects. Unlike standard options, these treatments utilize a combination of doxorubicin, cyclophosphamide, and paclitaxel, with the addition of pegfilgrastim or G-CSF to boost white blood cell counts and reduce infection risk. Each arm explores different dosing schedules and durations, potentially allowing for more personalized and effective treatment plans. This approach could lead to optimized treatment outcomes and improved patient experiences compared to traditional chemotherapy regimens.

What evidence suggests that this trial's treatments could be effective for breast cancer?

This trial will evaluate the effectiveness of different dosing schedules for a combination of three drugs—doxorubicin, cyclophosphamide, and paclitaxel—in treating breast cancer. Studies have shown that this combination attacks cancer cells in different ways: doxorubicin and cyclophosphamide damage the DNA of cancer cells, stopping their growth, while paclitaxel interferes with cell division, aiding in killing the cancer cells. Research has indicated that administering these drugs more frequently, known as dose-dense chemotherapy, can reduce the risk of cancer recurrence by about 28% over five years. This approach gives patients a better chance of remaining cancer-free for a longer period. Participants in this trial will be assigned to different treatment arms to assess the impact of various dosing schedules on treatment outcomes. ^{6 7 8 9 10}

Who Is on the Research Team?

Halle C Moore, MD

Principal Investigator

The Cleveland Clinic

George Thomas Budd, MD

Principal Investigator

The Cleveland Clinic

Are You a Good Fit for This Trial?

This trial is for patients who've had surgery for stage I-III breast cancer. Eligible participants must have operable disease with no T4 tumors, high-risk features based on tumor size and nodal status, and known hormone receptor status. HER2/neu-positive tumors are allowed. Those with HIV, prior malignancy within 5 years (except certain skin or in situ cancers), or previous chemotherapy with specific drugs cannot join.

Inclusion Criteria

I have had surgery to remove breast cancer and affected lymph nodes.

My cancer is at an early or mid-stage and can be operated on.

I know my cancer's estrogen and progesterone receptor status.

Exclusion Criteria

My tumor is not HER2 positive.

I haven't had cancer in the past 5 years, except for certain skin cancers or early-stage cervical or breast cancer.

My tumor is smaller than 1 cm and doesn't meet certain criteria.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive doxorubicin, cyclophosphamide, and paclitaxel in various regimens as adjuvant therapy for breast cancer

24-30 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

5 years

Every 6 months

Long-term follow-up

Participants are monitored annually for up to 15 years

10 years

Annually

What Are the Treatments Tested in This Trial?

Interventions

• Cyclophosphamide
• Doxorubicin Hydrochloride
• Paclitaxel

Trial Overview

The study compares two post-surgery chemo regimens using doxorubicin hydrochloride, cyclophosphamide, and paclitaxel to see which is more effective against resected breast cancer. It's a phase III trial where patients are randomly assigned to one of the two drug combinations.

How Is the Trial Designed?

Group I: Arm VI Experimental Treatment 5 Interventions

Patients receive doxorubicin, cyclophosphamide, and pegfilgrastim as in arm V. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 1 hour on day 1. Treatment repeats every 7 days for 12 courses.

Group II: Arm V Experimental Treatment 5 Interventions

Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 4 courses. Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 3 hours on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses.

Group III: Arm IV Experimental Treatment 5 Interventions

(closed 11/10/10) Patients receive doxorubicin, cyclophosphamide, and G-CSF as in arm II. Beginning 2 weeks after completion of cyclophosphamide, patients receive paclitaxel as in arm III.

Group IV: Arm II Experimental Treatment 5 Interventions

(closed 11/10/10) Patients receive doxorubicin IV on day 1, oral cyclophosphamide on days 1-7, and G-CSF SC on days 2-7. Treatment repeats every 7 days for 15 courses. Beginning 2 weeks after completion of cyclophosphamide, patients receive paclitaxel and pegfilgrastim as in arm I.

Group V: Arm I Active Control 5 Interventions

(closed 11/10/10) Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim subcutaneously (SC) on day 2 or filgrastim (G-CSF) SC on days 3-10. Treatment repeats every 14 days for 6 courses. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 3 hours on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses.

Group VI: Arm III Active Control 5 Interventions

(closed 11/10/10) Patients receive doxorubicin, cyclophosphamide, and pegfilgrastim or G-CSF as in arm I. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 1 hour on day 1. Treatment repeats every 7 days for 12 courses.

Cyclophosphamide is already approved in United States, European Union, Canada, Japan for the following indications:

Approved in United States as Cytoxan for:

• Breast cancer
• Ovarian cancer
• Multiple myeloma
• Leukemia
• Lymphoma
• Rheumatoid arthritis

Approved in European Union as Endoxan for:

• Breast cancer
• Ovarian cancer
• Multiple myeloma
• Leukemia
• Lymphoma
• Rheumatoid arthritis

Approved in Canada as Neosar for:

• Breast cancer
• Ovarian cancer
• Multiple myeloma
• Leukemia
• Lymphoma
• Rheumatoid arthritis

Approved in Japan as Endoxan for:

• Breast cancer
• Ovarian cancer
• Multiple myeloma
• Leukemia
• Lymphoma

Who Is Running the Clinical Trial?

SWOG Cancer Research Network

Lead Sponsor

Trials

403

Recruited

267,000+

Southwest Oncology Group

Lead Sponsor

Trials

389

Recruited

260,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Published Research Related to This Trial

The combination of intravenous paclitaxel and bolus doxorubicin is an effective primary chemotherapy for stage IV breast cancer, showing significant activity with manageable side effects.

Limiting the total dose of doxorubicin to 360 mg/m2 and using granulocyte colony-stimulating factor can reduce the risk of cardiotoxicity and neutropenia, while continuing treatment with paclitaxel can enhance the chances of a complete response in patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Experience at the Istituto Nazionale Tumori with paclitaxel in combination with doxorubicin in women with untreated breast cancer. Gianni, L., Capri, G.[2015]

Paclitaxel has shown high effectiveness in treating advanced breast cancer, including cases resistant to anthracyclines, prompting research into its combination with anthracyclines like doxorubicin.

Clinical trials of the paclitaxel/doxorubicin combination have reported promising response rates, although the toxicity profiles vary significantly based on the administration schedule used.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Paclitaxel and doxorubicin in metastatic breast cancer. Gehl, J., Boesgaard, M., Paaske, T., et al.[2015]

A randomized trial by the Eastern Cooperative Oncology Group (ECOG) is comparing the effectiveness of single-agent doxorubicin, single-agent paclitaxel, and their combination in treating metastatic breast cancer, with initial results currently being analyzed.

ECOG is also exploring ways to reduce the cardiac toxicity associated with doxorubicin by adding dexrazoxane, while ongoing trials are investigating the combination of carboplatin and paclitaxel to enhance treatment efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Paclitaxel doublets in metastatic breast cancer: Eastern Cooperative Oncology Group and Hoosier Oncology Group Studies. Sledge, GW.[2015]

In a study involving 2,305 women with primary breast cancer, intensifying the dose of cyclophosphamide in combination with doxorubicin did not lead to significant improvements in disease-free survival (DFS) or overall survival after 5 years.

Increasing the total dose of cyclophosphamide resulted in higher grade 4 toxicity, indicating that such intensification may not be safe or beneficial for patients outside of clinical trials.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. Fisher, B., Anderson, S., Wickerham, DL., et al.[2017]

The TEC regimen, which includes docetaxel, epirubicin, and cyclophosphamide, demonstrated a pathologic complete response rate of 25% in a phase II study involving 20 patients with locally advanced breast cancer.

The treatment was well-tolerated, with a 5-year overall survival rate of 94.7% and no cases of cardiac failure or treatment-related deaths, although neutropenia was a common side effect in 35% of patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer. Yao, X., Hosenpud, J., Chitambar, CR., et al.[2021]

The ASTER study demonstrated that a 6-month perioperative chemotherapy regimen combining Doxorubicin and Paclitaxel followed by Cyclophosphamide, Methotrexate, and 5-Fluorouracil is safe and effective for breast cancer treatment, with a low incidence of severe toxicities (8.5% grade III-IV hematologic toxicity).

With a follow-up of 6.7 years, the study reported high disease-free survival rates (99.6% at 1 year, 97.1% at 5 years) and overall survival rates (99.6% at 1 year, 94.9% at 5 years), indicating that this chemotherapy regimen is comparable in efficacy to other standard treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study. Mariani, G., Galli, G., Cavalieri, S., et al.[2019]

Docetaxel, particularly in combination with doxorubicin and cyclophosphamide (the TAC regimen), has been established as an effective treatment for node-positive breast cancer, demonstrating significant efficacy in both metastatic and adjuvant settings.

While the TAC regimen is associated with higher toxicity compared to traditional treatments, the side effects can be managed effectively with colony-stimulating growth factor support, making it a viable option for patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer. Martin, M.[2016]

In a study of 47 elderly women with high-risk breast cancer, the combination of Non-Pegylated Liposomal Doxorubicin (NPL-DOX) and Cyclophosphamide followed by weekly Paclitaxel showed a low rate of cardiac toxicity over a median follow-up of 76 months, with only one case of grade 3 congestive heart failure reported.

While there was a gradual decline in left ventricular ejection fraction (LVEF) over time, it remained above 50% and did not lead to any significant clinical symptoms, indicating that the treatment is relatively safe for cardiac health in this patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study. Coltelli, L., Finale, C., Musettini, G., et al.[2023]

Paclitaxel (Taxol) is an effective chemotherapy agent for treating ovarian cancer and metastatic breast cancer, particularly in patients who have not responded to platinum-based treatments.

Nurses must be aware of the potential side effects of Paclitaxel, such as hypersensitivity reactions and peripheral neuropathy, and follow specific administration guidelines to avoid complications related to its interaction with PVC intravenous-giving sets.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Paclitaxel (Taxol)--a guide to administration. Preston, NJ.[2019]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC4105484/

Comparison of Doxorubicin and Cyclophosphamide Versus ...

National Surgical Adjuvant Breast and Bowel Project trial B-15 showed that the four cycles of cyclophosphamide and doxorubicin (AC) was equivalent to six cycles ...

2.

consultqd.clevelandclinic.org

consultqd.clevelandclinic.org/research-offers-further-insight-into-chemo-scheduling-for-early-breast-cancer

Researchers Study Chemo Scheduling for Early Breast Cancer

Phase 3 trial found no survival differences between weekly or biweekly doxorubicin/cyclophosphamide or between weekly or biweekly paclitaxel.

3.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC6381879/

Adjuvant Dose-Dense Chemotherapy for Breast Cancer

The dose-intense treatment resulted in a 28% reduction in the relative risk of relapse in 5 years (event-free survival of 62% in the conventional arm and 70% in ...

4.

clinicaltrials.gov

clinicaltrials.gov/study/NCT00004067

Study Details | NCT00004067 | Doxorubicin and ...

This randomized phase III trial is studying how well giving combination chemotherapy together with trastuzumab works compared to combination chemotherapy alone.

5.

lbbc.org

lbbc.org/about-breast-cancer/treatments/chemotherapy/common-regimens/ac-t-doxorubicin

AC-T Chemotherapy Regimen

Doxorubicin damages the DNA inside the cancer cells ; Cyclophosphamide attaches to and damages the DNA in cancer cells ; Paclitaxel works by damaging the ...

6.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC4048960/

Cardiac Safety Analysis of Doxorubicin and ...

The combination of the anthracycline doxorubicin with cyclophosphamide (AC) is standard adjuvant therapy for early-stage breast cancer, as it significantly ...

7.

ar.iiarjournals.org

ar.iiarjournals.org/content/39/8/4379

Safety and Relative Dose Intensity of Dose-dense ...

Between May 2015 and Aug 2017, 44 patients with breast cancer who were administered 4 cycles of ddAC-P, doxorubicin (60 mg/m2), and cyclophosphamide (600 mg/m2) ...

8.

clinicaltrials.gov

clinicaltrials.gov/study/NCT00004067

NCT00004067 | Doxorubicin and Cyclophosphamide Plus ...

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2.

9.

ascopubs.org

ascopubs.org/doi/10.1200/jco.2010.28.15_suppl.594

Preliminary safety data of a randomized phase III trial ...

Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen ...

10.

acsjournals.onlinelibrary.wiley.com

acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.28284

Long‐term cardiac safety and outcomes of dose‐dense ...

In trial A, patients received dd doxorubicin and cyclophosphamide (AC)→paclitaxel (T) (each given every 2 weeks) × 4 with trastuzumab (H) given ...